Menu
Search
|

Menu

Close
X

Jounce Therapeutics Inc JNCE.OQ (NASDAQ Stock Exchange Global Select Market)

21.72 USD
-1.38 (-5.97%)
As of Feb 23
chart
Previous Close 23.10
Open 23.10
Volume 94,215
3m Avg Volume 76,516
Today’s High 23.10
Today’s Low 21.53
52 Week High 29.29
52 Week Low 11.05
Shares Outstanding (mil) 32.19
Market Capitalization (mil) 554.71
Forward P/E 7,903.67
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
59
FY16
37
FY15
0
EPS (USD)
FY17
-0.249
FY16
-6.969
FY15
-0.733
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
7,903.67
32.90
Price to Sales (TTM)
vs sector
7.13
5.77
Price to Book (MRQ)
vs sector
3.12
5.41
Price to Cash Flow (TTM)
vs sector
137.44
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
4.65
14.43
Return on Equity (TTM)
vs sector
0.82
16.13

EXECUTIVE LEADERSHIP

Perry Karsen
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Richard Murray
President, Chief Executive Officer, Director, Since 2014
Salary: $445,500.00
Bonus: $196,100.00
James Allison
Co-Founder, Since
Salary: --
Bonus: --
Thomas Gajewski
Co-Founder, Since
Salary: --
Bonus: --
Drew Pardoll
Co-Founder, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

780 Memorial Dr
CAMBRIDGE   MA   02139-4613

Phone: +1857.2593840

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. The Company’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates Inducible T cell CO-Stimulator (ICOS) and is in a Phase II trial.

SPONSORED STORIES